- Report
- May 2025
- 193 Pages
Global
From €3126EUR$3,545USD£2,697GBP
€3474EUR$3,939USD£2,996GBP
- Report
- May 2025
- 197 Pages
Global
From €3126EUR$3,545USD£2,697GBP
€3474EUR$3,939USD£2,996GBP
- Report
- April 2025
- 175 Pages
Global
From €3960EUR$4,490USD£3,416GBP
- Report
- June 2025
- 150 Pages
Global
From €2380EUR$2,699USD£2,053GBP
- Report
- May 2024
- 140 Pages
Global
From €5732EUR$6,499USD£4,944GBP
- Report
- January 2022
- 115 Pages
Global
From €4189EUR$4,750USD£3,613GBP
- Report
- February 2024
- 86 Pages
Global
From €3500EUR$4,251USD£3,125GBP
Velaglucerase alfa is a recombinant form of glucocerebrosidase, an enzyme used to treat Gaucher disease, a rare genetic disorder that affects the metabolism of lipids. It is a type of endocrine and metabolic disorder drug, and is administered intravenously. Velaglucerase alfa works by replacing the missing enzyme in the body, allowing it to break down fatty substances that accumulate in the organs and tissues of patients with Gaucher disease.
Velaglucerase alfa is approved by the US Food and Drug Administration (FDA) and is available in many countries around the world. It is marketed by several companies, including Shire, Pfizer, and Sanofi. It is also available in generic forms from other manufacturers. Show Less Read more